Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
Healthcare
$4.16 -0.81%
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
52W Low $0.38High $2.45
Volume 0.10M
Average 2.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$90.33M
FY 2025 · Annual
Investing Cash Flow
-$557,000.00
FY 2025 · Annual
Financing Cash Flow
$104.96M
FY 2025 · Annual
+3.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (38.74M) | (46.45M) | (77.09M) | (68.69M) | (140.95M) |
| Depreciation & Amortization | 676K | 452K | 286K | 677K | 1.13M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.09M | 3.14M | 4.3M | 14.43M | 6.68M |
| Change in Working Capital | 1.71M | (1.24M) | 989K | 9.59M | (395K) |
| Accounts Receivables | 0 | 0 | (22K) | 22K | 0 |
| Inventory | 0 | 0 | (73K) | 0 | 73K |
| Accounts Payables | 666K | 0 | (427K) | 2.69M | (1.67M) |
| Other Working Capital | 1.05M | (1.24M) | 1.51M | 6.88M | 1.2M |
| Other Non-Cash Items | 795K | (2.14M) | 28.7M | (21.52M) | 43.21M |
| Operating Cash Flow | (33.46M) | (46.24M) | (42.82M) | (65.52M) | (90.33M) |
| Capital Expenditures | (51K) | (56K) | (359K) | (1.77M) | (557K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (51K) | (56K) | (359K) | (1.77M) | (557K) |
| Debt Repayment | (7K) | 4.03M | 28.35M | (187K) | (457K) |
| Common Stock Issued | 0 | 321K | 0 | 103.7M | 105.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 40K | 0 | (911K) | (2.28M) | 0 |
| Financing Cash Flow | 99.88M | 4.35M | 27.44M | 101.23M | 104.96M |
| Effect of Forex Changes | 0 | (4.26M) | 0 | 0 | 0 |
| Net Change in Cash | 66.37M | (46.2M) | (15.75M) | 33.94M | 14.08M |
| Free Cash Flow | (33.51M) | (46.3M) | (43.18M) | (67.29M) | (90.89M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$141.0M
+ D&A$1.1M
+ Stock-Based Comp$6.7M
+ Deferred Tax$0
- Working Capital-$395.0K
+ Other Non-Cash$43.2M
= Operating Cash Flow-$90.3M
- Capex-$557.0K
= Free Cash Flow-$90.9M
Analysis
FY2025 free cash flow is -$90.9M. FCF conversion is 64.5% of net income. Operating cash flow was -$90.3M, with capex of -$557.0K. The largest bridge item is Other Non-Cash at $43.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 16, 2026 | |
| 8-K | Current report | Sep 11, 2026 | |
| DEF 14A | DEF 14A filing | Aug 24, 2026 | |
| PRE 14A | PRE 14A filing | Aug 14, 2026 |
Does GUTS generate free cash flow?
Fractyl Health, Inc. Common Stock (GUTS) generated -$90.89M of free cash flow in fiscal 2025.
How much operating cash flow does GUTS produce?
Operating cash flow was -$90.33M, before capital expenditures of $557,000.00.
Continue the stock analysis
Jump to another research area for this company.